40,735 Shares of Kiniksa Pharmaceuticals International, plc $KNSA Bought by Sowell Financial Services LLC

Sowell Financial Services LLC bought a new stake in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) during the third quarter, HoldingsChannel reports. The firm bought 40,735 shares of the company’s stock, valued at approximately $3,039,000.

Other institutional investors have also modified their holdings of the company. Robeco Institutional Asset Management B.V. bought a new position in shares of Kiniksa Pharmaceuticals International during the third quarter worth about $1,046,000. USA Financial Formulas bought a new stake in Kiniksa Pharmaceuticals International in the third quarter valued at about $69,000. TD Waterhouse Canada Inc. increased its holdings in Kiniksa Pharmaceuticals International by 3.9% in the third quarter. TD Waterhouse Canada Inc. now owns 17,343 shares of the company’s stock valued at $1,304,000 after buying an additional 652 shares during the last quarter. B. Riley Wealth Advisors Inc. bought a new stake in Kiniksa Pharmaceuticals International in the third quarter valued at about $763,000. Finally, GAMMA Investing LLC increased its holdings in Kiniksa Pharmaceuticals International by 21.1% in the third quarter. GAMMA Investing LLC now owns 1,278 shares of the company’s stock valued at $95,000 after buying an additional 223 shares during the last quarter. Institutional investors and hedge funds own 53.95% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on KNSA shares. Citigroup upped their price objective on Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. Canaccord Genuity Group lifted their target price on Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Zacks Research lowered Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 30th. JPMorgan Chase & Co. boosted their price target on Kiniksa Pharmaceuticals International from $72.00 to $107.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. Finally, Wells Fargo & Company initiated coverage on Kiniksa Pharmaceuticals International in a report on Wednesday, September 30th. They issued an “overweight” rating and a $87.00 price target for the company. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $93.14.

Insider Activity

In other Kiniksa Pharmaceuticals International news, Director G. Bradley Cole sold 3,673 shares of the firm’s stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $81.43, for a total value of $299,092.39. Following the transaction, the director owned 11,672 shares of the company’s stock, valued at $950,450.96. This trade represents a 23.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Michael R. Megna sold 4,600 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $80.30, for a total value of $369,380.00. Following the completion of the transaction, the chief accounting officer owned 29,062 shares of the company’s stock, valued at approximately $2,333,678.60. The trade was a 13.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 51.98% of the stock is owned by corporate insiders.

Kiniksa Pharmaceuticals International Stock Performance

Shares of NASDAQ:KNSA opened at $79.70 on Thursday. The stock has a market capitalization of $6.22 billion, a price-to-earnings ratio of 82.16 and a beta of 0.04. Kiniksa Pharmaceuticals International, plc has a 1-year low of $35.20 and a 1-year high of $84.06. The company’s fifty day moving average is $78.07 and its two-hundred day moving average is $64.76.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings results on Tuesday, July 28th. The company reported $0.30 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.30. Kiniksa Pharmaceuticals International had a net margin of 9.59% and a return on equity of 13.65%. The company had revenue of $243.60 million for the quarter, compared to the consensus estimate of $226.49 million. Sell-side analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.37 EPS for the current fiscal year.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.